Comparison of In Vitro Testing Antifungal Activity between Rosemary Essentials Oil and Fluconazol on Candida species Isolate from HIV/AIDS Patients with Candidiasis Oral
Downloads
Background: The most common opportunistic infection obtained in patients with Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) is Oral Candidiasis (OC). Currently widely reported about increased fluconazole resistance, as a therapy that is often used in patients with HIV/AIDS with OC. For this reason, effective antifungal agents are needed as alternative therapies. Several studies have reported some antifungal activity from rosemary essential oils. Purpose: The aim of this study is to evaluate the antifungal activity between rosemary essential oils and fluconazole against the isolates used by Candida sp. taken from HIV / AIDS patients with OC. Methods: This research was an experimental laboratory study with a post-test only design of 40 Candida sp. isolates from HIV / AIDS patients with OC in the Outpatient Unit and Inpatient Installation of the Infectious Disease Intermediate Care Unit (UPIPI) Dr. Soetomo General Academic Teaching Hospital, Surabaya. Examination of antifungal activity using conventional test methods with disk diffusion. Result: Disk diffusion test result revealed average inhibition zone of rosemary essential oil in Candida albicans 1,75±3,64 mm and Candida non-albicans 1,5±3,08 mm, while the average inhibition zone of fluconazole in Candida albicans 17,9±8,62 mm and Candida non-albicans 4,85±7,9 mm. There was significant difference (p <0.001) between the inhibition zone formed in Candida albicans by fluconazole and rosemary essential oil, but no significant difference of inhibition zone formed in Candida non-albicans. Conclusion: Antifungal activity fluconazole has greater than Rosemary essential oils in Candida albicans.
Moges B, Bitew A, Shewaamare A. Spectrum and the in vitro antifungal susceptibility pattern of yeast isolates in Ethiopian HIV patients with oropharyngeal candidiasis. Int J Micro 2016; 2016: 1-8.
Kundu RV, Garg A. Yeast Infection: Tinea (Pityriasis) Versicolor, Malassezia (Pityrosporum) Folliculitis. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell D, Wolff K, editors. Fitzpatrick's Dermatology in General Medicine. 8th ed. New York: McGraw-Hill; 2012. p. 2298-311.
Direktorat Jendral Pengendalian Penyakit dan Penyehatan Lingkungan Kementerian Kesehatan. Situasi penyakit HIV & AIDS di Indonesia. Jakarta: Ditjen PP & PL Kementerian Kesehatan RI; 2016. Available from: http://www. pusdatin.kemenkes.go.id/ (Accessed: 05 August 2019)
Shahapur PR, Bidri RC. Recent trends in the spectrum of opportunistic infections in Human Immunodeficiency Virus infected individuals on antiretroviral therapy in South India. J Nat Sci Biol Med 2014; 5(2): 392–6.
Dewi ISL, Hidayati AN. Manifestasi kelainan kulit pada pasien HIV dan AIDS. BIKKK 2015; 27(2): 97-105.
Reza NR, Sugiman T, Basuki S. Uji kepekaan in vitro flukonazol terhadap spesies Candida penyebab kandidiasis oral pada pasien HIV/AIDS dengan Vitek II. BIKKK 2017; 29(3): 234-42.
Widaty S, Soebono H, Nilasari H, Listiawan MY, Siswati AS, Triwahyudi D, et al, editors. Panduan Praktik Klinis Bagi Dokter Spesialis Kulit dan Kelamin di Indonesia. Jakarta: PP Perdoski; 2017.
Suyoso S, Ervianti E, Barakbah J. Kandidiasis Mukosa. In: Suyoso S, Ervianti E, Barakbah J, editors. Panduan praktik klinis SMF Ilmu Kesehatan Kulit dan Kelamin RSUD Dr. Soetomo, Surabaya 2014. p. 95-7.
Sobel JD, Akins RA. The role of resistance in candida infections: Epidemiology and treatment. In: Mayer DL, Sobel JD, Ouellette M, Kaye KS, Marchaim D, editors. Antimicrobial drug resistance. 2nd ed. New York: Springer International Publishing 2017. p. 1075-997.
Murtiastutik D, Maharani CS, Rahmadewi. Profile of Candida resistancy of fluconazole in male patient with oral candidiasis and HIV/AIDS. J AIDS Clin Res 2019; 10:1-6.
Gauch L, Pedrosa SS, Esteves RA, Silviera-Gomes F, Gurgel ESC, Arruda AC, et al. Antifungal activity of Rosmanirus officinalis Linn. essential oil against Candida albicans, Candida dubliniensis, Candida parapsilosis and Candida krusei. Rev Pan-Amaz Saude 2014; 5: 61-6.
Delich DN, Skrobonja JR, Karaman MA, Matavulj MN, Bogavac MA. Antifungal activity of essential oils of Origanum vulgare and Rosmarinus officinalis against three Candida albicans strains. J Nat Sci 2013; 124: 203-11.
Putranti A, Asmarawati TP, Rachman BE, Hadi U, Nasronudin. Oral Candidiasis clinical manifestation of HIV/AIDS infection in Airlangga University hospital patients. ICTROMI 2018; 125:1-6.
Nugraha AP, Ernawati DS, Parmadiati AE, Soebadi B, Triyono EA, Prasetyo RA, et al. Prevalence of Candida species in oral candidiasis and correlation with CD4+ count in HIV/AIDS patients in Surabaya, Indonesia. J Int Dent Med 2018; 11:1-5.
Barbara DA, Gary WP, Philippe D, Jeff F, Annette WF, Ghannoum MA, et al. M60: Performance standards for antimicrobial disk susceptibility. CLSI 2018; 37: 1-3.
Whaley SG, Berkow EL, Rybak JM, Nishimoto AT, Barker KS, Rogers PD, et al. Azole Antifungal Resistance in Candida albicans and Emerging Non- albicans Candida Species. Front Microbiol 2017; 7(January): 1–12.
- Copyright of the article is transferred to the journal, by the knowledge of the author, whilst the moral right of the publication belongs to the author.
- The legal formal aspect of journal publication accessibility refers to Creative Commons Atribusi-Non Commercial-Share alike (CC BY-NC-SA), (https://creativecommons.org/licenses/by-nc-sa/4.0/)
- The articles published in the journal are open access and can be used for non-commercial purposes. Other than the aims mentioned above, the editorial board is not responsible for copyright violation
The manuscript authentic and copyright statement submission can be downloaded ON THIS FORM.
